CommercialCoverageMedium impact
08.00.25o, Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents
Independence Blue Cross·Pulmonology, Cardiology, Internal Medicine·Pharmacy
Effective date
Apr 21, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated medical necessity criteria for pulmonary artery hypertension treatments using intravenous, subcutaneous, and inhaled pharmacologic agents. This affects pharmacy benefits and coverage determinations for specialized PAH medications.
Action Required
By April 21, 2025: Review updated medical necessity criteria for pulmonary artery hypertension drug treatments. Billing team should verify current prior authorization requirements for IV, subcutaneous, and inhaled PAH medications. Providers treating PAH patients should review documentation requirements to ensure compliance with new criteria.